source
- New U.S. hepatitis B vaccine policy targeting only at-risk newborns could raise infant infections and costs, studies warnA new U.S. recommendation limits the birth‑dose hepatitis B vaccine to infants who are judged to be at risk of neonatal infection, rather than offering it universally to all newborns. One study co…
- Oruka's yearly injectable shows 63% complete clearance in mid-stage psoriasis trialOruka Therapeutics reported results from a Phase 2 trial of its long-acting injectable, ORKA-001, in patients with plaque psoriasis. In the study, 63% of participants achieved complete skin cleara…